Compare Consolidated Edison, Inc. (ED) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Cassava Sciences Inc — how do they compare? Consolidated Edison, Inc. trades at $105.89 (market cap $39.20B), while Cassava Sciences Inc trades at $0.84 (market cap $39.40M). The key difference: Consolidated Edison, Inc. is far larger — about 994.9× Cassava Sciences Inc's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Cassava Sciences Inc for 37 Days on average.
| ED | FLNA | |
|---|---|---|
Market Cap | $39.20B | $39.40M |
Volume | 2,142,900 | 759,018 |
Sector | Utilities | Health |
52-Week High | $115.46 | $4.64 |
52-Week Low | $95.37 | $0.68 |
Typical Hold Time | 75 Days | 37 Days |
Enterprise Value | $66.05B | -$43.28M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $104.65, down 0.45% on the day, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The company maintains solid fundamentals with a P/E of 17.43, net income margin of 12.53%, and a $0.89 dividend. Revenue grew to $16.92B in 2025, with cash flow from operations strong at $4.80B. Analyst consensus is a Hold with a $106.33 price target, slightly above the current price.
ED's outlook is stable, supported by its utility business model and dividend aristocrat status, but faces risks from high debt levels and interest expenses. The stock offers income appeal with moderate growth potential, though investor sentiment is cautious amid mixed analyst ratings and institutional selling trends noted in recent filings.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
